WhichPeps

Maridebart cafraglutide

Long-acting antibody–peptide conjugate: GLP-1 receptor agonist / GIP receptor antagonist

Obesitytype 2 diabetes
Generic peptide vial illustrationMaridebart cafraglutide
Evidence levelHuman Phase II
Human evidencePhase II
Regulatory statusInvestigational / not authorised

What you need to know in 20 seconds

What is it?Long-acting antibody–peptide conjugate: GLP-1 receptor agonist / GIP receptor antagonist
Research focusObesity, type 2 diabetes, cardiovascular outcomes
Human evidencePhase II data show substantial weight loss and HbA1c improvement in adults with obesity, including those with type 2 diabetes; GI tolerability improved with lower starting doses/escalation.
Regulatory statusInvestigational; Phase 3 chronic-weight-management and cardiovascular studies are underway. No marketing authorisation identified.
Main limitationsMarketing approval, long-term cardiovascular outcomes, rare-event safety or real-world effectiveness.
SafetyGI adverse effects were common; escalation reduced tolerability burden in Phase 2.
i
Phase II data show substantial weight loss and HbA1c improvement in adults with obesity, including those with type 2 diabetes; GI tolerability improved with lower starting doses/escalation.

What the evidence actually supports

  • ✓Promising long-acting modality; do not equate convenience with proven superiority.
  • ✓Adds a separate metabolic outcome beyond the headline obesity endpoint.
  • ✓Useful safety/design outcome for comparisons with weekly GLP-1 therapies.

What is not established / key limitations

  • ×GI adverse events common; Phase 3 outcomes and long-term safety pending.
  • ×No marketing approval or long-term outcome evidence yet.
  • ×No evidence that less-frequent dosing eliminates class-related GI adverse effects.

Selected study & evidence records

Once-Monthly Maridebart Cafraglutide for the Treatment of Obesity — Phase 2

2025 · Randomized, double-blind, placebo-controlled dose-ranging trial · n=592

Obesity cohort mean change ranged -12.3% to -16.2% vs -2.5%; obesity+T2D -8.4% to -12.3% vs -1.7%.

Study detail → Primary source ↗

Safety and unknowns

GI adverse effects were common; escalation reduced tolerability burden in Phase 2.

Gastrointestinal adverse events were common in Phase 2, with better tolerability when dose escalation and lower starting doses were used. Long-term rare-event safety remains under study.

Technical details

Mechanism / biologyCombines GLP-1 receptor agonism with GIP receptor antagonism in a long-acting antibody-peptide conjugate intended for monthly or less-frequent dosing.
Route / formulation boundaryMaridebart cafraglutide is a long-acting antibody-peptide conjugate, not a conventional peptide vial.
Identity / data-quality noteAvoid calling MariTide simply a peptide; it is an antibody-peptide conjugate.
Dosing evidence statusPhase 2 dose-ranging verified. Phase 2 studied 140, 280 or 420 mg every 4 weeks and a 420 mg every-8-week arm, with different escalation schedules.
Identifiers & alternate namesMariTide · AMG 133

Evidence rule: WhichPeps keeps human, animal, laboratory, regulatory and product/formulation evidence distinct. Common names help people find the page; they do not change the underlying scientific identity.